Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 27Active not recruiting 9Not yet recruiting 5Completed 4Terminated 2Withdrawn 1Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neoplasms 18Breast Neoplasms 16Leukemia, Myeloid, Acute 15Glioblastoma 13Colorectal Neoplasms 13Prostatic Neoplasms 12Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 10Pancreatic Neoplasms 9Lung Neoplasms 9Glioma 8Carcinoma, Hepatocellular 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 7Head and Neck Neoplasms 7Carcinoma, Renal Cell 7Ovarian Neoplasms 6Myelodysplastic Syndromes 6Hematologic Neoplasms 6Triple Negative Breast Neoplasms 5Rectal Neoplasms 5Melanoma 5Uterine Cervical Neoplasms 4Sarcoma 4Colonic Neoplasms 4Brain Neoplasms 4Solid Tumor 3Small Cell Lung Carcinoma 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

TAK-243 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Anemia, Refractory, with Excess of Blasts × 1 year × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡